Department of Medicine (DIMED), University of Padova, Via Giustiniani 2, 35128, Padova, Italy.
International Renal Research Institute of Vicenza (IRRIV), Vicenza, Italy.
Sci Rep. 2022 Mar 2;12(1):3474. doi: 10.1038/s41598-022-07490-z.
Acute kidney injury (AKI) is associated with increased mortality in most critical settings. However, it is unclear whether its mild form (i.e. AKI stage 1) is associated with increased mortality also in non-critical settings. Here we conducted an international study in patients hospitalized with SARS-CoV-2 infection aiming 1. to estimate the incidence of AKI at each stage and its impact on mortality 2. to identify AKI risk factors at admission (susceptibility) and during hospitalization (exposures) and factors contributing to AKI-associated mortality. We included 939 patients from medical departments in Moscow (Russia) and Padua (Italy). In-hospital AKI onset was identified in 140 (14.9%) patients, mainly with stage 1 (65%). Mortality was remarkably higher in patients with AKI compared to those without AKI (55 [39.3%] vs. 34 [4.3%], respectively). Such association remained significant after adjustment for other clinical conditions at admission (relative risk [RR] 5.6; CI 3.5- 8.8) or restricting to AKI stage 1 (RR 3.2; CI 1.8-5.5) or to subjects with AKI onset preceding deterioration of clinical conditions. After hospital admission, worsening of hypoxic damage, inflammation, hyperglycemia, and coagulopathy were identified as hospital-acquired risk factors predicting AKI onset. Following AKI onset, the AKI-associated worsening of respiratory function was identified as the main contributor to AKI-induced increase in mortality risk. In conclusion, AKI is a common complication of Sars-CoV2 infection in non-intensive care settings where it markedly increases mortality risk also at stage 1. The identification of hospital-acquired risk factors and exposures might help prevention of AKI onset and of its complications.
急性肾损伤(AKI)与大多数危急情况下的死亡率增加有关。然而,其轻度形式(即 AKI 1 期)是否也与非危急情况下的死亡率增加有关尚不清楚。在这里,我们对因 SARS-CoV-2 感染住院的患者进行了一项国际研究,旨在:1. 估计每个阶段 AKI 的发生率及其对死亡率的影响;2. 确定入院时(易感性)和住院期间(暴露)的 AKI 危险因素以及导致 AKI 相关死亡率的因素。我们纳入了来自莫斯科(俄罗斯)和帕多瓦(意大利)医疗部门的 939 名患者。在住院期间,有 140 名(14.9%)患者出现 AKI 发作,主要为 1 期(65%)。与无 AKI 的患者相比,有 AKI 的患者死亡率明显更高(分别为 55 [39.3%] 和 34 [4.3%])。在调整入院时其他临床情况(相对风险 [RR] 5.6;95%CI 3.5-8.8)或仅纳入 AKI 1 期(RR 3.2;95%CI 1.8-5.5)或仅纳入 AKI 发作先于临床情况恶化的患者后,这种关联仍然显著。住院后,缺氧损伤、炎症、高血糖和凝血功能障碍恶化被确定为预测 AKI 发作的医院获得性危险因素。在 AKI 发作后,AKI 引起的呼吸功能恶化被确定为导致 AKI 增加死亡率风险的主要因素。总之,AKI 是非重症监护环境中 SARS-CoV2 感染的常见并发症,即使在 1 期也明显增加死亡率风险。确定医院获得性危险因素和暴露可能有助于预防 AKI 发作及其并发症。